Welcome to SynAging SAS

Your R&D partner for in vitro and in vivo phenotypic models in wild type, accelerating drug discovery for sporadic neurodegenerative diseases.

News

SynAging has new phone and fax numbers in 2017! Please amend your records accordingly. The old numbers will work until the end of 2017 only!

SynAging will be present at the following meetings in 2017:

Neuroscience R&D Technologies Conference, September 28-29, London, UK - Presentation on Sept. 29

Genesis Drug Discovery, October 11-12, Frankfurt Main, Germany - Presentation on Oct. 11

BIO-Europe 2017, November 6-8, Berlin, Germany

BioFIT 2017, November 28-29, Strassbourg, France, meet us at booth C4

SynAging' past meetings in 2017:

European Brain & Behavior Society Meeting, September 8-11, Bilbao, Spain

20 Years of alpha-synuclein in Parkinsion's disease and related synucleopathies Meeting in Athens, September 7-10, 2017

EuroTau Meeting, April 27-28, Lille, France

International Conference on Alzheimer's & Parkinson’s Diseases 2017 - Booth 14a, at the entrance of the exhibition & Posters
March 29 . – April 2., Vienna, Austria

SynAging's past meetings in 2016:

Press & Publications

SynAging's Poster won the 'Best Poster Award' during the '20 Years of alpha-synuclein in Parkinsion's disease and related synucleopathies' meeting in Athens, September 7-10, 2017 entitled:
PATHOLOGICAL ALPHA-SYNUCLEIN PREPARATIONS INDUCE COGNITIVE IMPAIRMENT AND NEURODEGENERATION
Download PDF
 

Poster EBBS Meeting 2017: PRION-LIKE SOLUBLE MISFOLDED PROTEIN OLIGOMERS INDUCE NEURODEGENERATION: RELEVANCE FOR PARKINSON’S AND ALZHEIMER’S DISEASE MODELS
Download PDF

Dietary arachidonic acid increases deleterious effects of amyloid-β oligomers on learning abilities and expression of AMPA receptors: putative role of the ACSL4-cPLA2 balance;  Link

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy
Link

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease
Link

HUMAN TAU OLIGOMERS INDUCE NEURODEGENERATION: TAUOPATHY MODELS FOR TARGET VALIDATION AND DRUG DEVELOPMENT
Download PDF

HUMAN ALPHA-SYNUCLEIN OLIGOMERS BUT NOT 'SPREADING' FIBRILS INDUCE EARLY COGNITIVE DECLINE IN MICE
Download PDF

SynAging's human tau oligomer poster at SFN 2016
Download PDF

SynAging's alpha synuclein oligomer poster at SFN 2016
Download PDF

SynAging's Alzheimers disease poster at AAIC 2016
Download PDF

SynAging's Parkinson's disease poster at AAIC 2016
Download PDF

 

Business and Partners

Since its founding in 2010, SynAging has investigated more than 1000 compounds in vitro and more than 100 compounds in vivo for more than 20 clients.

Obviously not all our partners are interested in being named as collaborators and we respect their confidentiality.
Consequently we are highly grateful to our valued customers that agreed to be represented below.

http://www.roche.fr http://www.actelion.com http://www.domaintherapeutics.com http://www.probiodrug.de
http://www.servier.com/ http://www.glpg.com/ http://www.proximagen.com/ http://www.lundbeck.com
http://promisneurosciences.com      

 

Research partners:

https://www.mti-globalstem.com

 

http://b-neuro.com

University of Manchester, UK
http://www.inserm.fr/
Inserm, Paris, France
http://www.avidinbiotech.com/
Avidin Biotech, Hungary
http://www.uni-goettingen.de
Prof. Bayer, University of Göttingen, Germany
 

 

SynAging is supported by the following institutional partners:

http://www.univ-lorraine.fr/ http://www.lorraine-inside.com

http://www.bpifrance.fr

 

http://incubateurlorrain.org/

Memberships:

http://www.lorraine-inside.com/ alz.org    

 

Sponsorship

SynAging sponsors the GDR-3545 (Groupement de Recherche) project, founded by CNRS, focusing on G protein-coupled receptors – “from physiology to drugs”, founded in 2012 (www.gdr3545.com).